These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29128554)

  • 1. Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study.
    Marinelli Busilacchi E; Costantini A; Viola N; Costantini B; Olivieri J; Butini L; Mancini G; Scortechini I; Chiarucci M; Poiani M; Poloni A; Leoni P; Olivieri A
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):267-275. PubMed ID: 29128554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic immune monitoring of CD4
    Lu Z; Xu N; Zhou X; Gao G; Li L; Huang J; Li Y; Lu Q; He B; Pan C; Liu X
    Oncol Lett; 2017 Aug; 14(2):1363-1372. PubMed ID: 28808483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
    Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
    Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
    El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
    J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
    Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
    Akashi N; Matsumoto I; Tanaka Y; Inoue A; Yamamoto K; Umeda N; Tanaka Y; Hayashi T; Goto D; Ito S; Sekiguchi K; Sumida T
    Mod Rheumatol; 2011 Jun; 21(3):267-75. PubMed ID: 21188449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
    Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
    J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
    Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
    Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.
    Walter GJ; Evans HG; Menon B; Gullick NJ; Kirkham BW; Cope AP; Geissmann F; Taams LS
    Arthritis Rheum; 2013 Mar; 65(3):627-38. PubMed ID: 23280063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
    Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
    BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
    Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
    Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
    Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
    Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shaping of CD56
    Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2019; 10():547. PubMed ID: 30949182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.
    Varda-Bloom N; Danylesko I; Shouval R; Eldror S; Lev A; Davidson J; Rosenthal E; Volchek Y; Shem-Tov N; Yerushalmi R; Shimoni A; Somech R; Nagler A
    Oncotarget; 2017 Jan; 8(1):418-429. PubMed ID: 27880933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid hormone differentially modulates the in vitro expansion and cytokine profile of thymic and splenic Treg cells.
    Pap R; Ugor E; Litvai T; Prenek L; Najbauer J; Németh P; Berki T
    Immunobiology; 2019 Mar; 224(2):285-295. PubMed ID: 30612787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.
    Geisler K; Reischer A; Kroeger I; Jacobs B; Meinhardt K; Bauer R; Ryffel B; Mackensen A; Ullrich E
    Oncol Rep; 2014 May; 31(5):2015-20. PubMed ID: 24626639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.